The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations ; volume:264 ; number:12 ; day:6 ; month:9 ; year:2017 ; pages:2351-2374 ; date:12.2017
Journal of neurology ; 264, Heft 12 (6.9.2017), 2351-2374, 12.2017
- Classification
-
Medizin, Gesundheit
- Creator
-
Pardo, Gabriel
- Contributor
-
Jones, David E.
SpringerLink (Online service)
- DOI
-
10.1007/s00415-017-8594-9
- URN
-
urn:nbn:de:1111-201801167082
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pardo, Gabriel
- Jones, David E.
- SpringerLink (Online service)
Other Objects (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers